Healx lands $56m to power artificial intelligence-led drug discovery
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
A new reality for Immunocore
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
Should the diabetes development road end for Sanofi?
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Autolus slams on the brakes in its Car
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Novartis needs new launches to keep up momentum
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
Back to the drawing board for Sumitomo’s deal-making
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Twilight of the stem cell transplant adjuncts?
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Which direction for Turning Point?
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.